Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

Core Insights - The phase 2 trial results for UBT251, a triple agonist for type 2 diabetes, show significant efficacy in reducing HbA1c and body weight compared to placebo and semaglutide [2][7][8] Company Overview - United Laboratories International Holdings Limited (TUL) is engaged in the research, development, production, and sales of pharmaceuticals, ranking among the leading integrated pharmaceutical companies in China [11] - TUL's subsidiary, United Biotechnology, is responsible for the development of UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nordisk handles the rest of the world [2][10] Clinical Trial Results - The trial enrolled 211 Chinese patients with type 2 diabetes, showing a mean HbA1c reduction of 2.16% for UBT251 compared to 1.77% for semaglutide and 0.66% for placebo after 24 weeks [2][6][7] - UBT251 also demonstrated a mean body weight reduction of up to 9.8%, compared to 4.8% for semaglutide and 1.4% for placebo [2][7] - Key secondary endpoints, including waist circumference, blood pressure, and lipids, showed improvements with UBT251 relative to placebo [3] Future Developments - TUL plans to advance to phase 3 trials in China based on the positive phase 2 results [4][5] - Novo Nordisk will initiate a global phase 2 trial for UBT251 in type 2 diabetes later in 2026 and is already conducting a global phase 2 trial in weight management [4][5]